Carregant...
FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
This retrospective review assesses the frequency of surrogate measures used for the first time vs subsequent times in a cancer setting and the surrogate’s strength of correlation with patient-centered outcomes.
Guardat en:
| Publicat a: | JAMA Intern Med |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Medical Association
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7186918/ https://ncbi.nlm.nih.gov/pubmed/32338703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.1097 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|